Zegfrovy

News

Dizal set to bring lung cancer drug Zegfrovy to US

Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.

News

AbbVie turbocharges its US investment promise to $100bn

AbbVie finally agrees a most-favoured nation pricing deal with the US administration, with a $100 billion investment promise attached.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks